Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics

Abstract Over the last decade, nanotherapeutics gained increasingly important role in drug delivery because of their frequently beneficial pharmacokinetics (PK) and lower toxicity when compared to classical systemic drug delivery. In view of therapeutic payload delivery, convective transport is crucial for systemic distribution via circulatory system, but the target domain is tissue outside vessels where transport is governed by diffusion. Here, we have computationally investigated the understudied interplay of physical transports to characterize PK of payload of nanotherapeutics. The analysis of human vasculature tree showed that convective transport is still 5 times more efficient than diffusion suggesting that circulating and payload releasing drug vectors can contribute mostly to systemic delivery. By comparing payload delivery using systemic circulation and drug vectors to microenvironment, internalized vectors were the most efficient and showed Area under the Curve almost 100 higher than in systemic delivery. The newly introduced zone of influence parameter indicated that vectors, especially internalized, lead to the largest tissue fraction covered with therapeutically significant payload concentration. The internalization to microenvironment minimizes effects of plasma domain on payload extravasation from nanotherapeutics. The computed results showed that classical PK, which mostly relies on concentration profiles in plasma, sometimes might be inadequate or not sufficient in explaining therapeutic efficacy of nanotherapeutics. These results provide a deeper look into PK of drug vectors and can help in the design of better drug delivery strategies.

[1]  R K Jain,et al.  Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.

[2]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[4]  D. Hume,et al.  Unravelling mononuclear phagocyte heterogeneity , 2010, Nature Reviews Immunology.

[5]  A. Ziemys,et al.  The role of payload hydrophobicity in nanotherapeutic pharmacokinetics. , 2014, Journal of pharmaceutical sciences.

[6]  Mauro Ferrari,et al.  Hierarchical modeling of diffusive transport through nanochannels by coupling molecular dynamics with finite element method , 2011, J. Comput. Phys..

[7]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Kojic,et al.  Computer Modeling in Bioengineering: Theoretical Background, Examples and Software , 2008 .

[9]  Mauro Ferrari,et al.  Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.

[10]  Matthias G Wacker,et al.  Nanotherapeutics--product development along the "nanomaterial" discussion. , 2014, Journal of pharmaceutical sciences.

[12]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[13]  C. Presant,et al.  Tumor‐based pharmacokinetics has greater significance for anticancer drugs than does blood‐based pharmacokinetics , 2004, Clinical pharmacology and therapeutics.

[14]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[15]  N. Kojic,et al.  Transport in biological systems , 2011 .

[16]  C. Presant,et al.  Association of intratumoral pharmacokinetics of fluorouracil with clinical response , 1994, The Lancet.

[17]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[18]  C. Prestidge,et al.  Nanoparticle layers controlling drug release from emulsions. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  Kinam Park,et al.  Facing the truth about nanotechnology in drug delivery. , 2013, ACS nano.

[20]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[21]  A Ziemys,et al.  A multiscale MD-FE model of diffusion in composite media with internal surface interaction based on numerical homogenization procedure. , 2014, Computer methods in applied mechanics and engineering.

[22]  G Cumming,et al.  Morphometry of the Human Pulmonary Arterial Tree , 1973, Circulation research.

[23]  H. Derendorf,et al.  Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue , 2004, Antimicrobial Agents and Chemotherapy.

[24]  Mauro Ferrari,et al.  Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.